Perrigo (PRGO) Share-based Compensation (2013 - 2026)
Perrigo (PRGO) reported Share-based Compensation of $14.4 million for Q1 2026, up 24.14% year-over-year from $11.6 million in Q1 2025, and up 10.77% quarter-over-quarter from $13.0 million in Q4 2025.
Perrigo (PRGO) Share-based Compensation (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Share-based Compensation data on file, last reported at $14.4 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $14.4 million, up 24.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.4 million (down 4.97% YoY), and the FY2025 annual result was $54.6 million, down 15.22% from the prior year.
- Share-based Compensation advanced to $14.4 million in Q1 2026 per PRGO's latest filing, from $13.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $26.3 million in Q2 2022 and troughed at $5.9 million in Q3 2024.
- A 5-year average of $15.1 million and a median of $14.4 million in 2026 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation plunged 59.86% in 2024, then soared 123.73% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $8.2 million in 2022, then gained by 29.27% to $10.6 million in 2023, then soared by 87.74% to $19.9 million in 2024, then tumbled by 34.67% to $13.0 million in 2025, then grew by 10.77% to $14.4 million in 2026.
- Business Quant data shows PRGO's Share-based Compensation at $14.4 million in Q1 2026, $13.0 million in Q4 2025, and $13.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 36.86 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.04 Mn |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn | 14.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 14.40 Mn |
| Mar 28, 2026 | 14.40 Mn |
| Dec 31, 2025 | 13.00 Mn |
| Dec 31, 2025 | 13.00 Mn |
| Sep 27, 2025 | 13.20 Mn |
| Sep 27, 2025 | 13.20 Mn |
| Jun 28, 2025 | 16.80 Mn |
| Jun 28, 2025 | 16.80 Mn |
| Mar 29, 2025 | 11.60 Mn |
| Mar 29, 2025 | 11.60 Mn |
| Dec 31, 2024 | 19.90 Mn |
| Dec 31, 2024 | 19.90 Mn |
| Sep 28, 2024 | 5.90 Mn |
| Sep 28, 2024 | 5.90 Mn |
| Jun 29, 2024 | 23.00 Mn |
| Jun 29, 2024 | 23.00 Mn |
| Mar 30, 2024 | 15.60 Mn |
| Mar 30, 2024 | 15.60 Mn |
| Dec 31, 2023 | 10.60 Mn |
| Dec 31, 2023 | 10.60 Mn |